News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DiscoveRx Corporation Continues to Innovate with Solutions for Epigenetic Drug Discovery Programs


2/3/2012 7:04:25 AM

FREMONT, Calif.--(BUSINESS WIRE)--DiscoveRx Corporation today announced the availability of an industry leading platform for studying Bromodomains, an emerging class of epigenetic targets. The new platform designated as BROMOscan™, is based on the proven KINOMEscan™ technology and will enable high throughput screening, selectivity profiling and quantitative Kd determinations across several sub-families of bromodomains, including the BET family.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES